CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor

Oncogene

Volumn 33, Issue 4, 2014, Pages 504-513

  Wu, L ^a   Runkle, C ^a   Jin, H J ^a   Yu, J ^a,a   Li, J ^a   Yang, X ^a   Kuzel, T ^a   Lee, C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Androgen receptor; CCN3; NOV; Polycomb EZH2

Indexed keywords

ANDROGEN RECEPTOR; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; POLYCOMB GROUP PROTEIN; TRANSCRIPTION FACTOR EZH2; VORINOSTAT; NOV PROTEIN, HUMAN; TRANSCRIPTOME;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GENETICS; CARCINOGENESIS; CELL GROWTH; CELL STRAIN LNCAP; CHROMATIN ASSEMBLY AND DISASSEMBLY; DOWN REGULATION; ENHANCER REGION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHROMATIN IMMUNOPRECIPITATION; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; PROSTATE TUMOR; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTOME;

EID: 84896645492     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.602     Document Type: Article

References (38)

1. Lamont KR, Tindall DJ. Minireview: alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 2011; 25: 897-907.
2. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17: 443-454.
3. Lin B, Wang J, Hong X, Yan X, Hwang D, Cho JH et al. Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS One 2009; 4: e6589.
4. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 2011; 30: 2719-2733.
5. Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 2011; 474: 390-394.
6. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 2011; 20: 457-471.
7. Zhao JC, Yu J, Runkle C, Wu L, Hu M, Wu D et al. Cooperation between polycomb and androgen receptor during oncogenic transformation. Genome Res 2012; 22: 322-331.
8. Liu YN, Liu Y, Lee HJ, Hsu YH, Chen JH. Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol Cell Biol 2008; 28: 7096-7108.
9. Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 2007; 67: 967-975.
10. Lanzino M, Sisci D, Morelli C, Garofalo C, Catalano S, Casaburi I et al. Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells - identification of a novel androgen response element. Nucleic Acids Res 2010; 38: 5351-5365.
11. Jun JI, Lau LF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 2011; 10: 945-963.
12. Martinerie C, Viegas-Pequignot E, Guenard I, Dutrillaux B, Nguyen VC, Bernheim A et al. Physical mapping of human loci homologous to the chicken nov protooncogene. Oncogene 1992; 7: 2529-2534.
13. McCallum L, Price S, Planque N, Perbal B, Pierce A, Whetton AD et al. A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation. Blood 2006; 108: 1716-1723.
14. Ohgawara T, Kubota S, Kawaki H, Kurio N, Abd El Kader T, Hoshijima M et al. Association of the metastatic phenotype with CCN family members among breast and oral cancer cells. J Cell Commun Signal 2011; 5: 291-299.
15. Zuo GW, Kohls CD, He BC, Chen L, Zhang W, Shi Q et al. The CCN proteins: important signaling mediators in stem cell differentiation and tumorigenesis. Histol Histopathol 2010; 25: 795-806.
16. McCallum L, Irvine AE. CCN3 - a key regulator of the hematopoietic compartment. Blood Rev 2008; 23: 79-85.
17. Perbal B. CCN3: Doctor Jekyll and Mister Hyde. J Cell Commun Signal 2008; 2: 3-7.
18. Benini S, Perbal B, Zambelli D, Colombo MP, Manara MC, Serra M et al. In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene 2005; 24: 4349-4361.
19. Maillard M, Cadot B, Ball RY, Sethia K, Edwards DR, Perbal B et al. Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues. Mol Pathol 2001; 54: 275-280.
20. Ouellet V, Tiedemann K, Mourskaia A, Fong JE, Tran-Thanh D, Amir E et al. CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone. Am J Pathol 2011; 178: 2377-2388.
21. Fukunaga-Kalabis M, Martinez G, Telson SM, Liu ZJ, Balint K, Juhasz I et al. Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene 2008; 27: 2552-2560.
22. Sin WC, Tse M, Planque N, Perbal B, Lampe PD, Naus CC. Matricellular protein CCN3 (NOV) regulates actin cytoskeleton reorganization. J Biol Chem 2009; 284: 29935-29944.
23. Vallacchi V, Daniotti M, Ratti F, Di Stasi D, Deho P, De Filippo A et al. CCN3/ nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res 2008; 68: 715-723.
24. Fu CT, Bechberger JF, Ozog MA, Perbal B, Naus CC. CCN3 (NOV) interacts with connexin43 in C6 glioma cells: possible mechanism of connexin-mediated growth suppression. J Biol Chem 2004; 279: 36943-36950.
25. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel RE. Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer 2004; 11: 781-791.
26. Bohlig L, Metzger R, Rother K, Till H, Engeland K. The CCN3 gene coding for an extracellular adhesion-related protein is transcriptionally activated by the p53 tumor suppressor. Cell Cycle 2008; 7: 1254-1261.
27. Kimura A, Martin C, Robinson GW, Simone JM, Chen W, Wickre MC et al. The gene encoding the hematopoietic stem cell regulator CCN3/NOV is under direct cytokine control through the transcription factors STAT5A/B. J Biol Chem 2010; 285: 32704-32709.
28. Bao BY, Chuang BF, Wang Q, Sartor O, Balk SP, Brown M et al. Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. Prostate 2008; 68: 839-848.
29. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007; 27: 380-392.
30. Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 2007; 12: 419-431.
31. Yu J, Cao Q, Yu J, Wu L, Dallol A, Li J et al. The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene 2010; 29: 5370-5380.
32. Wang XD, Wang BE, Soriano R, Zha J, Zhang Z, Modrusan Z et al. Expression profiling of the mouse prostate after castration and hormone replacement: implication of H-cadherin in prostate tumorigenesis. Differentiation 2007; 75: 219-234.
33. Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005; 11: 6823-6834.
34. Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007; 67: 10657-10663.
35. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrateresistant prostate cancer. Cancer Res 2009; 69: 958-966.
36. Joliot V, Martinerie C, Dambrine G, Plassiart G, Brisac M, Crochet J et al. Proviral rearrangements and overexpression of a new cellular gene (nov) in myeloblastosisassociated virus type 1-induced nephroblastomas. Mol Cell Biol 1992; 12: 10-21.
37. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138: 245-256.
38. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-243.